Literature DB >> 2509220

Regionally specific effects of acute and chronic nicotine on rates of catecholamine and 5-hydroxytryptamine synthesis in rat brain.

S N Mitchell1, M P Brazell, M H Joseph, M S Alavijeh, J A Gray.   

Abstract

Acute (-)-nicotine administration (0.4 and 0.8 mg/kg s.c.) produced a regionally specific increase in the rate of catecholamine synthesis in the rat nucleus accumbens, hypothalamus and hippocampus but not elsewhere, including the caudate-putamen. In all regions rates of 5-hydroxytryptamine synthesis were unaffected. (-)-Cotinine (0.4 and 0.8 mg/kg), the major metabolite of (-)-nicotine was without effect. (-)-Nicotine-induced increase in catecholamine synthesis occurred by a direct stimulation of central nicotinic receptors, as mecamylamine (5 mg/kg) but not hexamethonium (5 mg/kg) was an effective antagonist. Following repeated daily injections of (-)-nicotine (0.8 mg/kg) for up to 28 days, the induced catecholamine response following a subsequent challenge was unaffected in the nucleus accumbens and hypothalamus, but was increased in the hippocampus. This effect persisted for up to 14 days following withdrawal. Rates of 5-hydroxytryptamine synthesis remained unaltered after chronic pretreatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509220     DOI: 10.1016/0014-2999(89)90440-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid.

Authors:  E Toth; H Sershen; A Hashim; E S Vizi; A Lajtha
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

2.  Effects of environmental conditioning on the development of nicotine sensitization: behavioral and neurochemical analysis.

Authors:  M S Reid; L B Ho; S P Berger
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

Review 3.  Glucose for smoking cessation: does it have a role?

Authors:  R West
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Chronic oral nicotine administration affects the circadian rhythm of dopamine and 5-hydroxytryptamine metabolism in the striata of mice.

Authors:  K Pietila; I Laakso; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

5.  Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens.

Authors:  M Nisell; M Marcus; G G Nomikos; T H Svensson
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure.

Authors:  M H Joseph; S L Peters; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Nicotinic and muscarinic components of rat brain dopamine synthesis stimulation induced by physostigmine.

Authors:  J Grenhoff; T H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

8.  Relationship between up-regulation of nicotine binding sites in rat brain and delayed cognitive enhancement observed after chronic or acute nicotinic receptor stimulation.

Authors:  F A Abdulla; E Bradbury; M R Calaminici; P M Lippiello; S Wonnacott; J A Gray; J D Sinden
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

Review 9.  Exposure to nicotine and sensitization of nicotine-induced behaviors.

Authors:  P Vezina; D S McGehee; W N Green
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-09-01       Impact factor: 5.067

10.  The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.

Authors:  Shafiqur Rahman; Nichole M Neugebauer; Zhenfa Zhang; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Eur J Pharmacol       Date:  2008-10-26       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.